Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 103.10M P/E - EPS this Y 23.50% Ern Qtrly Grth -
Income -89.22M Forward P/E -0.75 EPS next Y -9.60% 50D Avg Chg -13.00%
Sales 21.05M PEG - EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 0.67 EPS next 5Y - 52W High Chg -64.00%
Recommedations 1.80 Quick Ratio 6.44 Shares Outstanding 48.59M 52W Low Chg 50.00%
Insider Own 0.91% ROA -24.79% Shares Float 22.43M Beta 0.90
Inst Own 78.83% ROE -71.29% Shares Shorted/Prior 419.69K/188.34K Price 2.17
Gross Margin - Profit Margin - Avg. Volume 1,562,280 Target Price 11.60
Oper. Margin -296.17% Earnings Date - Volume 32,734 Change -0.91%
About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TScan Therapeutics, Inc. News
04/24/24 TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
04/24/24 TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
04/22/24 TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
04/19/24 TScan Therapeutics Announces Closing of Upsized Public Offering
04/16/24 TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
04/16/24 TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
04/16/24 TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
04/08/24 TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
04/02/24 TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
03/26/24 Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%
03/17/24 Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
03/07/24 TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline
03/06/24 TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
03/06/24 TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
02/28/24 TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
02/26/24 TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
02/19/24 TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?
02/14/24 TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
02/06/24 TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
01/29/24 TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
TCRX Chatroom

User Image Stock_Titan Posted - 1 day ago

$TCRX TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-upcoming-presentations-at-the-2024-n8islnymryjx.html

User Image Stocks4thought Posted - 1 day ago

$TCRX Look In good

User Image CheckingMorons Posted - 1 day ago

$TCRX wow 98 % institutional jeez Christ this is very solid

User Image Stock_Titan Posted - 1 day ago

$TCRX TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-exercise-of-underwriters-option-to-xeyjlltqu3am.html

User Image Thestocktraderhubzee Posted - 1 day ago

WATCHLIST APR 24 2024 $TCRX Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $10 Price Target $SWN Stifel Maintains Hold on Southwestern Energy, Raises Price Target to $7.6 $VTLE Stifel Maintains Buy on Vital Energy, Raises Price Target to $75 $EOG Stifel Maintains Buy on EOG Resources, Lowers Price Target to $150 $CACI Stifel Maintains Buy on CACI International, Raises Price Target to $430

User Image soll Posted - 2 days ago

$TCRX https://ir.tscan.com/sec-filings/sec-filing/4/0000902664-24-003030

User Image soll Posted - 2 days ago

$TCRX Ownership and Control: Lynx1 Capital Management LP is a Delaware limited partnership that was formed in May 2020. The firm is owned and controlled by Weston Nichols, who serves as the Chief Investment Officer. Additionally, Lynx1 Capital Advisors LLC acts as the sub-adviser to the funds managed by Lynx1 Capital Management LP1. Recent Transaction: In a recent transaction, Lynx1 Capital Management LP, a significant shareholder in TScan Therapeutics, Inc. (NASDAQ: TCRX), acquired pre-funded warrants to purchase 5 million shares of the company’s common stock. These warrants were bought on April 19, 2024, at a price range of $7.1299 per share, resulting in a total investment of approximately $35.66 million. The pre-funded warrants allow the holder to purchase the company’s common stock at a predetermined price and come with certain terms and conditions2.

User Image Stock_Titan Posted - 3 days ago

$TCRX TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-upcoming-presentations-at-the-american-2sdqzsre679a.html

User Image Stocks4thought Posted - 3 days ago

$MRKR Major force soon ot $TCRX

User Image NorthWestHawk Posted - 6 days ago

Watching $TCRX. Will it bounce from its 50-day SMA at $7 in volume?

User Image Stock_Titan Posted - 6 days ago

$TCRX TScan Therapeutics Announces Closing of Upsized Public Offering https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-closing-of-upsized-public-3nis6cwh1xxx.html

User Image soll Posted - 1 week ago

$TCRX Peter Lawson Barclays Buy 04/18/24 $9.00 https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-zoetis-zts-and-tscan-therapeutics-tcrx

User Image DonCorleone77 Posted - 1 week ago

$TCRX TScan Therapeutics 2.473M share Spot Secondary priced at $7.13 The deal size was raised to $150M in common stock from $125M in common stock. Morgan Stanley and TD Cowen acted as joint book running managers for the offering.

User Image Jackofalltrade5 Posted - 1 week ago

$TCRX 3 tomorrow!?

User Image DonCorleone77 Posted - 1 week ago

$TCRX TScan Therapeutics announces $125M common stock offering TScan Therapeutics announced that it has commenced an underwritten public offering of $125M of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock. All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. The company intends to use the net proceeds from the offering for general corporate purposes. Morgan Stanley and TD Cowen are acting as joint book-running managers for the offering. LifeSci Capital is acting as Lead Manager, and BTIG, H.C. Wainwright & Co. and Needham & Company are each acting as co-managers for the offering.

User Image Stock_Titan Posted - 1 week ago

$TCRX TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-launch-of-125-million-proposed-public-9ruxzspm4hrh.html

User Image Stock_Titan Posted - 1 week ago

$TCRX TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-provides-clinical-pipeline-update-and-highlights-o1d4ckrg5zo7.html

User Image InsightInvestsub Posted - 1 week ago

🚀 Watching $TCRX closely! Analysts target $11, bullish EMAs signal strong momentum. Earnings drop May 7, could be a game-changer. Stay tuned for updates and join the discussion! 💡📈 #DayTrading #BiotechStocks https://open.substack.com/pub/insightinvestsub/p/tcrx-investment-newsletter-embrace?r=2brmn5&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

User Image Stocks4thought Posted - 1 week ago

$RANI LSD trips $TCRX $INDP

User Image Stocks4thought Posted - 2 weeks ago

$TCRX new high coming

User Image Stocks4thought Posted - 2 weeks ago

$TCRX Looking for $8 HCT Chimerism. OVER L(OOKED.

User Image Stocks4thought Posted - 2 weeks ago

$TCRX Dirt cheap

User Image Stocks4thought Posted - 2 weeks ago

$TCRX Life of Riley$

User Image Stock_Titan Posted - 3 weeks ago

$TCRX TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-upcoming-presentation-at-the-23rd-qw6jpd5qyt2f.html

User Image MRKR2025 Posted - 03/27/24

@type12 $IOVA $VINC $MAIA $BLUE $TCRX

User Image Stocks4thought Posted - 03/27/24

$TCRX $9 well that's on life in the day of a cat......................$8 more live to surpass $9

User Image kiwitc2000 Posted - 03/27/24

$TCRX Testing the nines. If it can hold it there's no resistance until the 12s. That would put it back at the IPO level.

User Image Stocks4thought Posted - 03/27/24

$TCRX $10 next stop.................$9.11 is the stepwise move. Hit that PPS...........ot $Vor platform is under appreciated.

User Image Stocks4thought Posted - 03/27/24

$TCRX Always been my absolute favorite---------- post $AMGN and the secondary----------$21 target...........Chimerism!

User Image FlynancialAnalyst Posted - 03/27/24

$TCRX institutions getting $INZY and loading this ~$380M mc $XBI name.

Analyst Ratings
Wedbush Outperform Apr 23, 24
Barclays Overweight Mar 7, 24
HC Wainwright & Co. Buy Mar 7, 24
Wedbush Outperform Feb 1, 24
HC Wainwright & Co. Buy Aug 14, 23
Wedbush Outperform Jun 22, 23
HC Wainwright & Co. Buy May 18, 23
HC Wainwright & Co. Buy May 11, 23
HC Wainwright & Co. Buy Mar 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BARBERICH TIMOTHY J Director Director Dec 18 Buy 4.93 29,147 143,695 67,027 12/21/23
BARBERICH TIMOTHY J Director Director Jun 02 Buy 2.6284 37,880 99,564 37,880 06/06/23
Lynx1 Capital Management LP 10% Owner 10% Owner May 31 Sell 2.51 25,400 63,754 5,224,600 06/02/23
BAKER BROS. ADVISORS LP Director Director May 10 Buy 1.89 1,359,792 2,570,007 2,528,583 05/12/22